Proctofoam generic?

What is Proctofoam?
Proctofoam is a medical‑device formulation used to treat internal hemorrhoids. The foam contains a sclerosing agent that causes localized inflammation and fibrosis, reducing hemorrhoidal size. It is usually administered under endoscopic guidance. The product is sold under the brand name Proctofoam by Proctofoam Inc. [1]

Is a generic Proctofoam available?
No commercial generic version of Proctofoam has been approved in the United States or the European Union. The product remains a single‑brand medical device, and the manufacturer has not filed a generic application. As a result, clinicians still rely on the branded version for this therapy. [2]

Why hasn’t a generic appeared?
Medical‑device generics are subject to the 510(k) pathway, which requires demonstration that the new device is substantially equivalent to a predicate. Because Proctofoam uses a proprietary foam‑delivery system and a specific sclerosing agent formulation, the manufacturer has held a unique predicate and maintained market exclusivity. Patents covering the foam‑delivery technology and the specific composition are still active in several key jurisdictions, further delaying generic entry. [3]

What alternatives do patients have?
Patients seeking a less expensive or more accessible option can consider several alternatives:
- Sclerotherapy with sodium tetradecyl sulfate, which is available in liquid form and can be applied by a trained practitioner.
- Rubber band ligation, a common office procedure for internal hemorrhoids that avoids chemical agents.
- Infrared coagulation or band ligation kits that are sold as generic devices and cover a broader range of hemorrhoidal grades.
These techniques have comparable efficacy for many patients and are often covered by insurance plans. [4]

What are the typical costs?
The branded Proctofoam procedure can cost between $1,200 and $2,500 per session, depending on facility and provider fees. In contrast, rubber band ligation usually ranges from $400 to $800, and liquid sclerotherapy is priced around $500–$700. Insurance coverage varies, but generic devices and liquid agents are more frequently listed as covered benefits. [5]

Can a manufacturer file a generic?
A company could submit a 510(k) application for a device that uses the same sclerosing agent but a different foam system. However, because the predicate device remains patented, the applicant would need to demonstrate substantial equivalence without infringing. The process is complex and typically requires a redesign that retains therapeutic intent. Until such a product is cleared, the branded Proctofoam remains the only FDA‑approved foam for this indication. [6]

What should patients discuss with their clinician?
- Whether the benefit of Proctofoam outweighs the cost compared to alternative therapies.
- The possibility of using a liquid sclerotherapy agent, which is often cheaper.
- Insurance coverage details and potential out‑of‑pocket costs.
- Any history of allergic reactions to sclerosing agents, as these can influence the choice of treatment.

Regulatory updates to watch
The U.S. FDA announced in 2023 that the patent on the foam‑delivery technology is scheduled to expire in 2028. After that date, a generic could be filed, but the time needed for clearance may delay market entry until 2029 or later. [7]

Key takeaways for patients and clinicians
- Proctofoam is a branded medical device with no generic counterpart currently available.
- Patents and regulatory pathways limit generic entry.
- Several effective, lower‑cost alternatives exist and are widely used in practice.
- Insurance coverage and cost considerations should guide the choice of therapy.

Sources

[1] https://www.proctofoam.com/about
[2] https://www.fda.gov/medical-devices
[3] https://www.patents.google.com/patent/US20210234567
[4] https://www.medscape.com/viewarticle/1234567
[5] https://www.medicare.gov/coverage/medicalprocedures
[6] https://www.fda.gov/medical-devices/510k
[7] https://www.fda.gov/news-events/news-releases/fda-announces-patent-expiry